How India Exports Carfilzomib to the World

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for carfilzomib, indicating the absence of generic versions in the U.S. market. The reference listed drug, Kyprolis (carfilzomib), received FDA approval on July 20, 2012. The regulatory pathway for carfilzomib involves a New Drug Application (NDA) submission, requiring comprehensive clinical data to demonstrate safety and efficacy. Given the absence of approved ANDAs, Indian exporters face limited opportunities in the U.S. market for generic carfilzomib. Additionally, the FDA's import alerts database does not currently list any alerts related to carfilzomib, suggesting no significant compliance issues for this product.

In the European Union, the European Medicines Agency (EMA) granted marketing authorization for Kyprolis (carfilzomib) on November 19, 2015. The authorization covers its use in combination therapies for adult patients with multiple myeloma who have received at least one prior therapy. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has adopted similar regulatory standards post-Brexit, ensuring continued access to carfilzomib. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these markets, necessitating rigorous quality assurance processes.

As of the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, carfilzomib is not included. This exclusion may influence procurement decisions in countries that rely on the WHO list for their national formularies. Regarding pharmacopoeial standards, carfilzomib is not currently monographed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP), which may impact quality control and regulatory assessments in various jurisdictions.

In India, carfilzomib is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for carfilzomib, allowing market-driven pricing. For export purposes, the Central Drugs Standard Control Organization (CDSCO) requires a No Objection Certificate (NOC), ensuring compliance with regulatory standards and monitoring of pharmaceutical exports.

Carfilzomib's primary patents have expired, opening the market to generic competition. However, the absence of approved ANDAs in the U.S. and limited marketing authorizations for generics in other regions suggest that generic versions are not yet widely available. This scenario presents an opportunity for Indian manufacturers to enter markets with high demand for cost-effective multiple myeloma treatments.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines. The 24th edition, published in September 2025, did not include carfilzomib, potentially affecting its adoption in national formularies. In April 2025, the EMA updated the product information for Kyprolis, reflecting new safety data and usage guidelines. In January 2026, the FDA issued guidance on the development of generic versions of complex drugs, including proteasome inhibitors like carfilzomib, aiming to facilitate the approval process for generics. In February 2026, the NPPA initiated a review of high-cost oncology drugs, including carfilzomib, to assess the need for price regulation. In March 2026, the CDSCO streamlined the export NOC process for pharmaceuticals, reducing approval times for exporters.

These developments underscore the dynamic regulatory environment affecting carfilzomib's global market presence and highlight opportunities for Indian exporters to navigate and capitalize on emerging trends.

Carfilzomib, a proteasome inhibitor used in multiple myeloma treatment, relies on complex Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). India, a significant producer of APIs, has historically depended heavily on China for KSMs, with imports accounting for over 70% of its bulk drug requirements. This dependency poses risks, as any disruption in Chinese supply chains can directly impact Indian pharmaceutical manufacturing. For instance, in July 2025, geopolitical tensions led to temporary export restrictions from China, causing delays in API production in India.

To mitigate such vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, launched in July 2020. By September 2025, this initiative had established domestic production capacities for 26 KSMs and APIs, reducing import reliance and enhancing supply chain resilience. However, the effectiveness of these measures in fully addressing the dependency on Chinese KSMs remains to be seen, especially for specialized compounds like those used in Carfilzomib.

Our proprietary trade data from 2022 to 2026 indicates that the top five exporters of Carfilzomib from India account for 17.1% of total exports, with MSN Laboratories Private Limited leading at a 7.5% share. This relatively low concentration suggests a diversified supplier base, which can mitigate risks associated with over-reliance on a single source. However, the presence of 65 active exporters also implies potential variability in quality and supply consistency.

The PLI Scheme for Pharmaceuticals, initiated in March 2021, aims to bolster domestic manufacturing capabilities and reduce import dependence. By December 2025, the scheme had attracted significant investments, leading to the production of 191 KSMs, Drug Intermediates (DIs), and APIs for the first time in India. While this initiative enhances overall pharmaceutical production, its direct impact on Carfilzomib's supply chain diversification requires further assessment.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. In August 2025, heightened tensions in the Strait of Hormuz led to increased shipping costs and delays, affecting the timely delivery of Carfilzomib to key markets such as Russia and Chile. Additionally, ongoing U.S.-China trade disputes have introduced uncertainties in the availability and pricing of raw materials essential for API production.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various oncology drugs in recent years. While Carfilzomib has not been specifically highlighted, the broader trend underscores the importance of proactive supply chain management to prevent potential disruptions.

• Diversify Raw Material Sources: Identify and qualify alternative suppliers for KSMs and APIs beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Supplier Relationships: Establish long-term contracts with key suppliers to ensure consistent quality and supply, mitigating risks associated with a fragmented exporter base.

• Enhance Regulatory Compliance: Monitor and adhere to international regulatory standards to prevent potential export restrictions and maintain market access.

• Invest in Domestic Manufacturing: Leverage government incentives under the PLI Scheme to develop in-house capabilities for critical APIs and KSMs, reducing reliance on imports.

• Implement Robust Logistics Planning: Develop contingency plans for shipping disruptions, including alternative routes and transportation modes, to ensure timely delivery of products to global markets.

RISK_LEVEL: MEDIUM